Dual-action cancer therapy with targeted porous silicon nanovectors

Anna Cifuentes Rius, Angela Ivask, Ester Sporleder, Ishdeep Kaur, Yasmin Assan, Shasha Rao, David Warther, Clive A Prestidge, Jean-Olivier Durand, Nicolas Voelcker

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)


There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.

Original languageEnglish
Article number1701201
Number of pages6
Issue number29
Publication statusPublished - 4 Aug 2017


  • Cancer
  • Cytotoxicity
  • Drug delivery
  • Nanoparticles

Cite this